Selecta Biosciences, Inc. (NASDAQ:SELB – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Selecta Biosciences in a research report issued to clients and investors on Tuesday, July 11th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings of ($0.40) per share for the year. The consensus estimate for Selecta Biosciences’ current full-year earnings is ($0.39) per share.
Selecta Biosciences (NASDAQ:SELB – Get Free Report) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The business had revenue of $5.94 million for the quarter, compared to the consensus estimate of $14.60 million. Selecta Biosciences had a negative net margin of 18.21% and a negative return on equity of 17.67%.
Selecta Biosciences Stock Up 3.6 %
SELB opened at $1.14 on Wednesday. The firm has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.35. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $174.91 million, a PE ratio of -12.67 and a beta of 1.14. Selecta Biosciences has a 52 week low of $0.90 and a 52 week high of $2.73.
Hedge Funds Weigh In On Selecta Biosciences
A number of institutional investors and hedge funds have recently bought and sold shares of SELB. Vanguard Group Inc. raised its stake in shares of Selecta Biosciences by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 6,146,460 shares of the company’s stock valued at $10,080,000 after acquiring an additional 614,373 shares during the period. BlackRock Inc. increased its holdings in shares of Selecta Biosciences by 1.8% in the 3rd quarter. BlackRock Inc. now owns 2,418,393 shares of the company’s stock valued at $3,965,000 after purchasing an additional 43,704 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in Selecta Biosciences during the 1st quarter valued at about $3,232,000. Marshall Wace LLP increased its holdings in Selecta Biosciences by 88.2% during the 3rd quarter. Marshall Wace LLP now owns 1,849,070 shares of the company’s stock valued at $3,032,000 after acquiring an additional 866,384 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Selecta Biosciences by 4.7% during the 1st quarter. State Street Corp now owns 1,790,985 shares of the company’s stock worth $2,203,000 after purchasing an additional 80,662 shares during the last quarter. 35.78% of the stock is currently owned by institutional investors and hedge funds.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia.
Further Reading
- Five stocks we like better than Selecta Biosciences
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
